Brand Name : Mektovi
Marketing Authorization Holder : Pierre Fabre
℞ Prescription Required
Mektovi is used to treat skin cancer (melanoma) in adults in combination with Braftovi (containing encorafenib). This combination may slow down or stop cancer growth.
Mektovi is recommended at a dose of 90mg daily, as 45 mg (three 15 mg tablets) twice daily (12 hours apart). In order to manage adverse reactions, dose reduction, interruption of therapy or treatment stoppage be required.
![]() |
![]() |
![]() |
![]() |